Safety and Efficacy of EVT 101 in Treatment-Resistant Depression
Status:
Terminated
Trial end date:
2011-03-01
Target enrollment:
Participant gender:
Summary
This study is a 4-week, randomized, double-blind, parallel-group, placebo-controlled
monotherapy study in patients with treatment-resistant major depression. After confirmation
of treatment-resistance in a prospective treatment period with citalopram, each patient will
be treated with either EVT 101 once daily or placebo for 28 consecutive days.